Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ted Brady

Pulmonary Disease Tamarac, FL Doctor of Osteopathy

NPI 1831150515 CMS profile 83050

7710 Nw 71St Ct, Suite 203, Tamarac, FL 33321

Open in the dashboard

General payments

$6,408

362 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ted Brady of Tamarac, FL is reported in the CMS Open Payments database as having received $6,408 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,173 59
2024 General $1,251 67
2023 General $1,097 60
2022 General $1,023 56
2021 General $568 34
2020 General $438 28
2019 General $859 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ted Brady
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ted Brady were reported at $1,173. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ted Brady Pulmonary Disease median Middle half National median
2019 $859 $377 $109–$1,340 $163
2020 $438 $230 $56–$907 $114
2021 $568 $269 $68–$1,072 $132
2022 $1,023 $390 $100–$1,457 $149
2023 $1,097 $419 $114–$1,659 $160
2024 $1,251 $476 $123–$1,818 $164
2025 $1,173 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,196 142 payments
  2. AstraZeneca Pharmaceuticals LP $834 47 payments
  3. Genzyme Corporation $606 26 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $568 36 payments
  5. Regeneron Healthcare Solutions, Inc. $494 18 payments
  6. Amgen Inc. $237 12 payments
  7. Grifols USA, LLC $231 13 payments
  8. Sunovion Pharmaceuticals Inc. $190 11 payments
  9. Mylan Specialty L.P. $145 8 payments
  10. United Therapeutics Corporation $136 7 payments
  11. Other $771 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,408 362 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,414 89 payments
  2. DUPIXENT Immunology $586 25 payments
  3. NUCALA $507 33 payments
  4. SPIRIVA RESPIMAT $456 31 payments
  5. DUPIXENT Inflammation And Immunology $399 15 payments
  6. FASENRA $358 17 payments
  7. TEZSPIRE $237 12 payments
  8. BREZTRI $235 12 payments
  9. Prolastin-C Liquid $231 13 payments
  10. STIOLTO RESPIMAT $226 14 payments
  11. Other $2,462 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

3,220

Median for Pulmonary Disease: 936

Drug cost

$889,409

Median for Pulmonary Disease: $487,987

Branded share of claims

72.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 513 $381,617
Breo Ellipta Fluticasone/Vilanterol Brand 308 $142,398
Spiriva Respimat Tiotropium Bromide Brand 142 $80,877
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 107 $60,994
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 75 $56,266
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 91 $42,364
Symbicort Budesonide/Formoterol Fumarate Brand 127 $37,071
Albuterol Sulfate Hfa Albuterol Sulfate Brand 625 $14,591
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 24 $12,354
Spiriva Handihaler Tiotropium Bromide Brand 21 $10,949

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$112,579

Of which drugs: $4,233

Medicare patients

530

Average age 75

Services billed

1,723

292 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
COPD 51%
Arthritis 46%
Diabetes 45%
Chronic kidney disease 41%
Heart failure 37%
Depression 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,176
Vaccine for influenza for injection into muscle 90662 Office 11 11 $832

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $231
  • Regeneron Healthcare Solutions, Inc. $95
$325 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $305
$305 513 —
TEZSPIRE
  • Amgen Inc. $102
  • AstraZeneca Pharmaceuticals LP $19
$121 — —
NUCALA
  • GlaxoSmithKline, LLC. $93
$93 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record